Center for Molecular Medicine Cologne

Prof. Dr. Oliver A Cornely - Curriculum Vitae

Education and professional career

2014: Scientific Director, CTCC
2014: Full Professor, Translational Research, CECAD Cologne
2008 - 2014: Professor, Internal Medicine (apl)
2007 - 2014: Medical Director, Clinical Trials Center Cologne (CTCC)
2006: Attending, lnfectious Diseases
2005 - 2006: Board Examination in lnfectious Diseases
2004: Habilitation
2001 - 2005: Board Examination in Hematology and Oncology
1999: Doctoral Thesis at the Dep. I of Internal Medicine, University of Cologne
1994: Medical License
1994 - 2001: Board Examination in Internal Medicine
1987 - 1994: Medical School, University of Cologne

Awards, distinctions and professional activities

2017: Founder & Chair, Infectious Diseases Working Group, Clinical Trial Site Network, European Hematological Association (EHA)
2017: Founder & Chair, FungiResearch Phase 1 & 2 Platform, Antiinfectives Development
2016: Founder, World-wide Excellence Center Program (ECMM)
2016: Founder, ECMM Academy
2016: Fellow, European Confederation of Medical Mycology (FECMM)
2016: Deputy Speaker, Partner Site BonnCologne (DZIF)
2016: Board of Directors, Mycoses Study Group (NIH-MSGERC)
2015: Fellow, American Academy of Microbiology (FAAM)
2015 - 2016: Advisory Board, Antimicrobial Resistance (ESCMID)
2014: Standards & Guidelines Committee, Inf. Dis. Society of America (IDSA)
2014: Pushpa Talwar Memorial Award, Postgraduate Institute, Chandigarh, India
2014: Advisory Board, German Society for Infectious Diseases (DGI)
2012: Lead, Translational Infrastructure Clinical Trial Unit, German Center for Infection Research (DZIF)
2012: Lead, National Hub, Innovative Medicines Initiative (IMI-COMBACTE)
2012 - 2017: Program Committee, Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC/MICROBE)
2011: Fellow, American College of Physicians (FACP)
2011 - 2017: President, European Confederation of Medical Mycology (ECMM)
2009: Faculty Prize, Best Publication, Faculty of Medicine, University of Cologne
2008: Fellow, lnfectious Diseases Society of America (IDSA)
2008 - 2011: President, German-Speaking Mycological Society (DMykG)

Selected publications

Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT (2017) Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis dx.doi.org/10.1016/ S1473-3099(17)30751-X.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB (2017) Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 376(4):305-17.

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd,  Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Rácil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JA, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJ (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16(7): 828-37.

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA (2015) Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162(2): 81-9.

Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G, Ozgunes I, Valia JC, Eggimann P, Leon C, Montravers P, Philips S, Tweddle L, Karas A, Brown M, Cornely OA (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61(11): 1671-8.

Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, Marchetti O, de Burghgraeve P, Ramadan S, Pylkkanen L, Ameye L, Paesmans M, Donnelly JP (2015) Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis 61(3): 324-31.

Bacher P, Steinbach A, Kniemeyer O, Hamprecht A, Assenmacher M, Vehreschild MJ, Vehreschild J, Brakhage A, Cornely OA, Scheffold A (2015) Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med 191(3): 348-52.

Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM (2014) Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59(3): 345-54.

Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S (2013) Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31(19): 2493-9.

Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12(4): 281-9.